Andrew S. Boyer
Net Worth

Last updated:

What is Andrew S. Boyer net worth?

The estimated net worth of Mr. Andrew S. Boyer is at least $9,863,408 as of 15 Aug 2024. He owns shares worth $2,351,097 as insider, has earned $612,311 from insider trading and has received compensation worth at least $6,900,000 in Amneal Pharmaceuticals, Inc..

What is the salary of Andrew S. Boyer?

Mr. Andrew S. Boyer salary is $1,150,000 per year as Executive Vice President & Chief Commercial Officer of Generics in Amneal Pharmaceuticals, Inc..

How old is Andrew S. Boyer?

Mr. Andrew S. Boyer is 59 years old, born in 1966.

What stocks does Andrew S. Boyer currently own?

As insider, Mr. Andrew S. Boyer owns shares in one company:

Company Title Shares Price per share Total value
Amneal Pharmaceuticals, Inc. (AMRX) Executive Vice President & Chief Commercial Officer of Generics 256,670 $9.16 $2,351,097

What does Amneal Pharmaceuticals, Inc. do?

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX logo
AMRX
Amneal Pharmaceuticals, Inc.
$9.16

Andrew S. Boyer insider trading

Amneal Pharmaceuticals, Inc.

Mr. Andrew S. Boyer has made 3 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 40,225 units of AMRX stock worth $315,766 on 15 Aug 2024.

The largest trade he's ever made was exercising 66,666 units of AMRX stock on 7 Aug 2019. As of 15 Aug 2024 he still owns at least 256,670 units of AMRX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Class A Common Stock 40,225 $7.85 $315,766
Sale
Class A Common Stock 22,486 $7.81 $175,616
Option
Restricted Stock Units 49,694 N/A N/A
Option
Class A Common Stock 49,694 N/A N/A
Option
Class A Common Stock 39,251 N/A N/A
Option
Restricted Stock Units 39,251 N/A N/A
Option
Restricted Stock Units 31,371 N/A N/A
Option
Class A Common Stock 31,371 N/A N/A
Option
Restricted Stock Units 31,663 N/A N/A
Option
Class A Common Stock 31,663 N/A N/A
Sale
Class A Common Stock 29,302 $4.13 $120,929
Option
Class A Common Stock 23,095 N/A N/A
Option
Restricted Stock Units 23,095 N/A N/A
Option
Class A Common Stock 39,251 N/A N/A
Option
Restricted Stock Units 39,251 N/A N/A
Option
Restricted Stock Units 31,371 N/A N/A
Option
Class A Common Stock 31,371 N/A N/A
Option
Class A Common Stock 12,346 N/A N/A
Option
Restricted Stock Units 12,346 N/A N/A
Option
Class A Common Stock 31,662 N/A N/A
Option
Restricted Stock Units 31,662 N/A N/A
Option
Class A Common Stock 23,094 N/A N/A
Option
Restricted Stock Units 23,094 N/A N/A
Option
Restricted Stock Units 16,656 N/A N/A
Option
Class A Common Stock 16,656 N/A N/A
Option
Restricted Stock Units 31,370 N/A N/A
Option
Restricted Stock Units 12,346 N/A N/A
Option
Class A Common Stock 31,370 N/A N/A
Option
Class A Common Stock 12,346 N/A N/A
Option
Restricted Stock Units 31,662 N/A N/A
Option
Class A Common Stock 31,662 N/A N/A
Option
Class A Common Stock 23,095 N/A N/A
Option
Restricted Stock Units 23,095 N/A N/A
Option
Class A Common Stock 16,655 N/A N/A
Option
Restricted Stock Units 16,655 N/A N/A
Option
Class A Common Stock 12,346 N/A N/A
Option
Restricted Stock Units 12,346 N/A N/A
Option
Restricted Stock Units 31,662 N/A N/A
Option
Class A Common Stock 31,662 N/A N/A
Option
Restricted Stock Units 16,656 N/A N/A
Option
Class A Common Stock 16,656 N/A N/A
Option
Restricted Stock Units 12,345 N/A N/A
Option
Class A Common Stock 12,345 N/A N/A
Purchase
Class A Common Stock 66,666 $2.89 $192,665
Purchase
Class A Common Stock 19,000 $9.46 $179,740
Option
Class A Common Stock 16,655 N/A N/A
Option
Restricted Stock Units 16,655 N/A N/A

Amneal Pharmaceuticals key executives

Amneal Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Mr. Anastasios G. Konidaris (58) Executive Vice President & Chief Financial Officer
  • Mr. Andrew S. Boyer (59) Executive Vice President & Chief Commercial Officer of Generics
  • Mr. Chintu Patel R.Ph., R.Ph (53) Co-Founder, Co-Chief Executive Officer & Director
  • Mr. Chirag K. Patel (58) Co-Founder, Co-Chief Executive Officer, Pres & Director
  • Mr. Joseph Todisco MBA (49) Executive Vice President & Chief Commercial Officer of Specialty
  • Ms. Nikita Shah (47) Executive Vice President and Chief HR Officer & Strategic Planning Officer